This bill directs the Secretary of State, working with the Secretary of Health and Human Services and other agencies, to write a global strategy to secure support from foreign countries, multilateral organizations, and other entities. The strategy must focus on helping develop and commercialize qualified pandemic or epidemic products, including products for antimicrobial-resistant or other priority pathogens. The Secretary must submit the strategy to specified congressional committees within 18 months of enactment. The bill lists what the strategy should cover, including how the United States would enter arrangements with partners, promote equitable contributions, strengthen partner country public health capacity, harmonize efforts, assign responsibilities for product development and commercialization, steward products developed, and consider contracts, public-private partnerships, payment models, coverage pathways, and regulatory streamlining. The strategy must align with existing U.S. preparedness strategies named in the bill.
No publicly available information.
The bill's findings state that emerging infectious diseases and antimicrobial-resistant pathogens threaten national security by raising the risk of outbreaks reaching the United States, disrupting infrastructure, harming the economy and public health, and affecting U.S. forces abroad. Supporters, as reflected in the bill text, argue that stronger international collaboration to develop, commercialize, and deploy pandemic or epidemic products, and improvements in partner countries' public health capabilities, will reduce the likelihood that global outbreaks reach the United States and will promote equitable access to medical countermeasures.
No publicly available information.